We are monitoring the impact of COVID-19 on APAC Prostate Cancer Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1539
Share on
Share on

APAC Prostate Cancer Market Research Report - Segmented By Diagnostic Techniques, Surgery, Radiation Therapy, Chemotherapy and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1539
Pages: 145

APAC Prostate Cancer Market Size (2021 to 2026)

The size of the prostate cancer market in the Asia Pacific is estimated to value USD 19.01 billion by 2026 from USD 11.46 billion in 2021, growing at a CAGR of 10.65% during the forecast period.

Prostate cancer is a common term used for the diseased situations in which abnormal cells grow and infect uncontrollably in the prostate. New product inventions, partnership agreements, collaborations, and acquisitions are some of the key strategies adopted by the players to get a significant market share in the forecast period.

Advancement in technology, personalized medicine, cost-effective treatment procedures are a few other factors expected to boost the Asia-Pacific prostate cancer market. RIn addition, the rising incidence of prostate cancers and the availability of various treatment modalities are also fuelling the market growth.

However, limited commercially available drugs and treatments for this cancer are the challenges restraining the growth of the prostate cancer market. Nevertheless, The Asia Pacific market is estimated to show a substantial growth rate deeds in promising countries.

This research report on the APAC prostate cancer market has been segmented and sub-segmented into the following categories.

By Diagnostic Techniques: 

  • Digital Rectal Exam (DRE)
  • Prostate-Specific Antigen Test (PSA)

By Surgery: 

  • Radical Prostatectomy
  • Orchidectomy
  • Trans Urethral Resection (TUR)

By Radiation Therapy: 

  • External Beam Radiation Therapy
  • Brachytherapy

By Chemotherapy: 

  • Docetaxel
  • Etoposide
  • Vinblastine
  • Carboplatin
  • Vinorelbine

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Asia-Pacific offers attractive potential for key players in the prostate cancer market due to increased awareness of prostate cancer treatment and acceptance of prostate cancer treatment products. In addition, improvements in healthcare infrastructure, an increase in the number of hospitals with modern medical facilities, a growing R&D sector, a rise in healthcare reforms, and technical advancements in the field of healthcare all contribute to market expansion. Over the forecast period, the market for castrate-resistant prostate cancer in the Asia Pacific is expected to grow rapidly. This is the case because of the existence of significant oncology firms and expanding R&D investments in nations like China and Japan. On the other hand, it has increased the development of prostate cancer drugs. Other factors driving the growth of the Asia-Pacific prostate cancer treatment market include leading manufacturers' increased focus on expanding their geographic presence in emerging Asia-Pacific countries to capitalize on high growth opportunities in the market, a large population base, and high disposable incomes.

Because China has a large population, the total number of tests is projected to be larger than in other regions. Therefore, China is expected to dominate the Asia-Pacific prostate cancer diagnostics market. Prostate cancer is, nonetheless, extremely common in Australia. The most significant rates of prostate cancer have been observed in Australia and New Zealand, owing to the widespread use of prostate-specific antigen (PSA) screening in these countries. However, prostate cancer incidence has been observed to differ from country to country in the Asia Pacific. Because Japan has a large geriatric population, the country is expected to gain a significant market share during the forecast period. To stay competitive, market companies are using various growth methods such as new product launches, mergers and acquisitions, government partnerships, and technological advancements to contribute significantly to market growth.

KEY MARKET PLAYERS:

Sanofi S.A, GlaxoSmithKline, AstraZeneca, AbbVie, Varian Medical Systems, Elekta, Theragenics, Pfizer, Novartis, Roche, Bayer, Johnson & Johnson, Abbott Laboratories, and Genentech are a few of the promising companies in the APAC prostate cancer market.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Diagnostic Techniques                           

                                5.1.1 Introduction           

                                5.1.2 Digital Rectal Exam (DRE)  

                                5.1.3 Prostate Specific Antigen Test (PSA)            

                                5.1.4 Y-o-Y Growth Analysis, By Product

                                5.1.5 Market Attractiveness Analysis, By Product               

                                5.1.6 Market Share Analysis, By Product                

                5.2 Surgery                        

                                5.2.1 Introduction           

                                5.2.2 Radical Prostatectomy       

                                5.2.3 Orchidectomy        

                                5.2.4 Trans Urethral Resection (TUR)      

                                5.2.5 Y-o-Y Growth Analysis, By Type      

                                5.2.6 Market Attractiveness Analysis, By Type     

                                5.2.7 Market Share Analysis, By Type      

                5.3 Radiation Therapy                   

                                5.3.1 Introduction           

                                5.3.2 External Beam Radiation Therapy  

                                                5.3.2.1 3D Conformal Radiation Therapy

                                                5.3.2.2 Intensity Modulated Radiation Therapy

                                                5.3.2.3 Stereotactic Body Radiation Therapy

                                                5.3.2.4 Proton Beam Radiation Therapy

                                5.3.3 Brachytherapy      

                                                5.3.3.1 Permanent Brachytherapy

                                                5.3.3.2 Temporary Brachytherapy

                                5.3.4 Y-o-Y Growth Analysis, By Application         

                                5.3.5 Market Attractiveness Analysis, By Application        

                                5.3.6 Market Share Analysis, By Application         

                5.4 Chemotherapy                         

                                5.4.1 Introduction           

                                5.4.2 Docetaxel

                                5.4.3 Etoposide

                                5.4.4 Vinblastine             

                                5.4.5 Carboplatin             

                                5.4.6 Vinorelbine            

                                5.4.7 Y-o-Y Growth Analysis, By Disease Indications          

                                5.4.8 Market Attractiveness Analysis, By Disease Indications        

                                5.4.9 Market Share Analysis, By Disease Indications         

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Diagnostic Techniques

                                                6.1.3.3 By Surgery

                                                6.1.3.4 By Radiation Therapy

                                                6.1.3.5 By Chemotherapy

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Diagnostic Techniques

                                                6.1.4.3 By Surgery

                                                6.1.4.4 By Radiation Therapy

                                                6.1.4.5 By Chemotherapy

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Diagnostic Techniques

                                                6.1.5.3 By Surgery

                                                6.1.5.4 By Radiation Therapy

                                                6.1.5.5 By Chemotherapy

                6.2 China                            

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea               

                6.6 Australia                      

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Sanofi S.A                    

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 GlaxoSmithKline                      

                8.3 AstraZeneca               

                8.4 AbbVie                         

                8.5 Varian Medical Systems                        

                8.6 Elekta                           

                8.7 Theragenics               

                8.8 Pfizer                            

                8.9 Novartis                       

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Prostate Cancer Market, By Diagnostic Techniques, From 2021 to 2026 (USD Million)
  2. Asia-Pacific Digital Rectal Exam (DRE) Market, By Region, From 2021 to 2026 (USD Million)
  3. Asia-Pacific Prostate Specific Antigen Test (PSA) Market, By Region, From 2021 to 2026 (USD Million)
  4. Asia-Pacific Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  5. Asia-Pacific Radical Prostatectomy Market, By Region, From 2021 to 2026 (USD Million)
  6. Asia-Pacific Orchidectomy Market, By Region, From 2021 to 2026 (USD Million)
  7. Asia-Pacific Trans Urethral Resection (TUR) Market, By Region, From 2021 to 2026 (USD Million)
  8. Asia-Pacific Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  9. Asia-Pacific External Beam Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  10. Asia-Pacific Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  11. Asia-Pacific Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  12. Asia-Pacific Docetaxel Market, By Region, From 2021 to 2026 (USD Million)
  13. Asia-Pacific Etoposide Market, By Region, From 2021 to 2026 (USD Million)
  14. Asia-Pacific Vinblastine Market, By Region, From 2021 to 2026 (USD Million)
  15. Asia-Pacific Carboplatin Market, By Region, From 2021 to 2026 (USD Million)
  16. Asia-Pacific Vinorelbine Market, By Region, From 2021 to 2026 (USD Million)
  17. Japan Prostate Cancer Market, By Diagnostic Techniques, From 2021 to 2026 (USD Million)
  18. Japan Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  19. Japan Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  20. Japan Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  21. China Prostate Cancer Market, By Diagnostic Techniques , From 2021 to 2026 (USD Million)
  22. China Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  23. China Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  24. China Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  25. India Prostate Cancer Market, By Diagnostic Techniques, From 2021 to 2026 (USD Million)
  26. India Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  27. India Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  28. India Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  29. Australia Prostate Cancer Market, By Diagnostic Techniques, From 2021 to 2026 (USD Million)
  30. Australia Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  31. Australia Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  32. Australia Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  33. South Korea Prostate Cancer Market, By Diagnostic Techniques, From 2021 to 2026 (USD Million)
  34. South Korea Prostate Cancer Market, By Surgery, From 2021 to 2026 (USD Million)
  35. South Korea Prostate Cancer Market, By Radiation Therapy, From 2021 to 2026 (USD Million)
  36. South Korea Prostate Cancer Market, By ChemoTherapy, From 2021 to 2026 (USD Million)
  37. Asia-Pacific Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  38. Asia-Pacific 3D Conformal Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  39. Asia-Pacific Intensity Modulated Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  40. Asia-Pacific Stereotactic Body Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  41. Asia-Pacific Proton Beam Radiation Therapy Market, By Region, From 2021 to 2026 (USD Million)
  42. Japan Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  43. China Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  44. India Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  45. Australia Prostate Cancer Market, By External Beam Radiation Therapy, From 2021 to 2026 (USD Million)
  46. Asia-Pacific Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  47. Asia-Pacific Permanent Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  48. Asia-Pacific Temporary Brachytherapy Market, By Region, From 2021 to 2026 (USD Million)
  49. Japan Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  50. China Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  51. India Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)
  52. Australia Prostate Cancer Market, By Brachytherapy, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample